Total
0
Shares
4DMedical (ASX:4DX) - CEO, Andreas Fouras - The Market Herald
CEO, Andreas Fouras
Source: Courier Mail
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical tech company 4DMedical (4DX) has secured the first U.S. clinical pilot of its XV Lung Ventilation Analysis Software (XV LVAS)
  • The company’s software pilot will be conducted at St. Joseph Hospital in California’s Orange County over the coming months
  • XV LVAS will be used to screen for various lung conditions, including asthma, emphysema, pulmonary fibrosis, lung cancer and COVID-19
  • This initial pilot marks the start of 4DMedical’s commercialisation phase in the United States
  • 4DMedical is down 0.44 per cent and trading at $2.25 per share

Medical tech company 4DMedical (4DX) has secured the first U.S. clinical pilot of its XV Lung Ventilation Analysis Software (XV LVAS).

The XV LVAS solution uses the company’s XV technology, which sequences of X-ray images into four-dimensional quantitative data. Using existing hospital equipment, the software can help diagnose respiratory diseases with greater sensitivity and speed. 

The first U.S. clinical trial of XV LVAS will be conducted at St Joseph Hospital in California’s Orange County over the coming months. The pilot will be the first time the software is used on clinic patients in the United States, and therefore marks the start of 4DMedical’s commercialisation phase there.

During the pilot, hospital physicians will use XV LVAS to screen patients for various lung conditions. These include asthma, emphysema, pulmonary fibrosis, lung cancer, and the COVID-19 virus.

St. Joseph Hospital will conduct a full review of the XV LVAS end-to-end solution during the clinical pilot.

4DMedical’s CEO, Andreas Fouras, commented on the company’s first U.S clinical pilot for XV LVAS.

“We are extremely pleased to announce the commencement of the clinical pilot in collaboration with St. Joseph Hospital as it signifies the commencement of our commercialisation phase in the U.S.,” he said.

“We believe that XV LVAS is a unique tool that can assist physicians in diagnosing and managing patients with various lung diseases, including COVID-19, as it provides physicians with a unique picture of how air moves in the lungs,” he added.

4DMedical is down 0.44 per cent and trading at $2.25 per share at 4:10 pm AEDT.

4DX by the numbers
More From The Market Herald
Patrys (ASX:PAB) selects stable cell line for PAT-DX1 production

" AFT Pharmaceuticals (ASX:AFP) signs exclusive Maxigesic IV licensing agreement

AFT Pharmaceuticals has signed an exclusive Maxigesic IV licensing agreement for eight new European markets.
Althea Group (ASX:AGH) - CEO, Joshua Fegan - The Market Herald

" Althea Group’s (ASX:AGH) subsidiary gets A$137K order to make cannabis concentrates

Althea Group’s (AGH) subsidiary, Peak Processing Solutions, has received an C$134,000 (roughly A$137,216) purchase order from Peace Naturals Project.
Immutep (ASX:IMM) - CEO, Marc Voigt (left) - The Market Herald

" Immutep (ASX:IMM) expands TACTI-002 study

Immutep (IMM) has expanded Part B of its TACTI-002 phase two trial, following a recommendation from the data monitoring committee.
ImpediMed (ASX:IPD) - CEO, Rick Carreon - The Market Herald

" ImpediMed (ASX:IPD) completes 200,000 patient tests

ImpediMed  (IPD) says it has reached a milestone 200,000 patient tests for SOZO testing.